Merck & Co. is set to enter the multi-billion dollar ophthalmology market with a deal to acquire EyeBio and its lead asset for $1.3bn upfront.
Merck & Co. To Enter Ophthalmology With EyeBio Buyout
Veteran developers stay on to accelerate development of potential first-in-class drug to challenge Bayer/Regeneron’s Eylea and Roche’s Vabysmo in a deal worth up to $3bn.
More from Clinical Trials
More from R&D
• By
The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares
• By
The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.
• By
A decision from the FDA is due by 28 September.